These were the biggest pharmaceutical deals in early 2022
GlobalData tracks the latest acquisitions, mergers, venture financing and asset transactions in the pharmaceutical sector.
By
GlobalData tracks the latest acquisitions, mergers, venture financing and asset transactions in the pharmaceutical sector.
ByThe data shows that M&A activity is strongest in the US, which saw a total of 19 deals announced in…
ByMerck has acquired Pandion Therapeutics for $1.85bn. The deal centres around Pandion’s TALON technology and immune modulators, which re-balance the…
ByHorizon has agreed to buy Viela for $3bn to expand its pipeline, as well as drive long-term growth. Viela has…
ByConsolidation in the pharmaceutical sector, with the biggest November deals happening in the US, was given a boost by China…
Merck has signed a definitive agreement to acquire VelosBio. The $2.75bn deal hinges around VelosBio’s ROR1-targeting antibody therapies, and particularly…
ByIn January, Aimmune’s Palforzia became the first drug approved for any food allergy. Nestlé Health Science, which has been involved…
ByBy acquiring Empirica and its work on glioblastoma (GBM), Century Therapeutics has taken its first step towards developing off-the-shelf cell…
ByThank you for subscribing to Pharmaceutical Technology